RT Journal Article
SR Electronic
T1 Metronidazole and <em>Giardia</em>: <em>in vitro</em> viability assay under microaerophilic conditions indicates a multifactorial basis for metronidazole treatment failure
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2025.02.26.25322590
DO 10.1101/2025.02.26.25322590
A1 Nohýnková, Eva
A1 Perglerová, Aneta
A1 Tůmová, Pavla
YR 2025
UL http://medrxiv.org/content/early/2025/02/28/2025.02.26.25322590.abstract
AB We developed a simple 24-hour viability assay to evaluate the tolerance of the parasite Giardia intestinalis to metronidazole (MTZ) in vitro. Our findings emphasize the importance of test conditions and evaluation parameters. Using this assay with minimum lethal concentration (MLC) as an evaluation parameter, we identified two isolates that are naturally tolerant to MTZ. Natural MTZ tolerance was detected only under microaerophilic conditions, as both isolates were susceptible to MTZ under anaerobic conditions. These isolates were derived from stool samples of patients with MTZ-refractory giardiasis, suggesting that the parasite tolerance was responsible for the failure of MTZ treatment. However, two other isolates from patients with MTZ-refractory giardiasis were susceptible under both test conditions, indicating that MTZ-refractory giardiasis likely has a multifactorial cause.HIGHLIGHTSIn vitro test conditions are significant to assess metronidazole tolerance in GiardiaIn vitro test should be done under both anaerobic and microaerophilic conditionsMLC, but not IC50, is a valuable parameter for evaluating MTZ toleranceFailure to treat giardiasis with metronidazole probably has a multifactorial causeCompeting Interest StatementThe authors have declared no competing interest.Funding StatementCzech Health Research Council (grant No. NU23-05-00441)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of University Hospital Bulovka, 180 81 Prague 8, Budinova 2, Czech Republic gave ethical approval for this work (protocol number: 6.6.20221 1 0480|EK-Z)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript